Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Guanidinopropionic Acid (GPA) is a creatine analogue that has been primarily studied in animal models for its metabolic effects. Its use as a treatment or support for Metabolic Syndrome is based on preclinical research rather than traditional use or widespread clinical adoption. Scientific studies, largely conducted in rodents, have shown that GPA can activate AMP-activated protein kinase (AMPK), a cellular energy sensor that plays a significant role in regulating glucose and lipid metabolism. Activation of AMPK is thought to improve insulin sensitivity, enhance glucose uptake in skeletal muscle, and promote fatty acid oxidation, all of which are beneficial mechanisms in the context of Metabolic Syndrome.

Experimental studies have demonstrated that GPA supplementation in rodents leads to reduced body weight, improved glucose tolerance, and decreased adiposity. However, these benefits have not yet been robustly demonstrated in human studies. There are no large-scale clinical trials or regulatory approvals for GPA in the management of Metabolic Syndrome in humans. Its use in this context is not supported by tradition or established clinical guidelines, and concerns remain about its safety profile and long-term effects.

In summary, while there is some scientific rationale based on animal data supporting the potential role of GPA in metabolic regulation, the evidence is limited and not yet translatable to clinical practice for Metabolic Syndrome. The current evidence score is low due to the lack of human data.

More about Guanidinopropionic Acid (GPA )
More about Metabolic Syndrome

Other ingredients used for Metabolic Syndrome

Other health conditions supported by Guanidinopropionic Acid (GPA )

Products containing Guanidinopropionic Acid (GPA )